Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 6/20 | 0.64 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.64 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.64 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.53 |
| ▸ | DPP4 | P27487 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6208549 | 0.98 | SLC6A4 (0.61) | SLC6A4SLC6A3SLC6A2HSD11B1DPP4 | |
| SCHEMBL17761202 | 0.90 | DPP4 (0.56) | SLC6A4SLC6A3SLC6A2HSD11B1DPP4 | |
| SCHEMBL4866308 | 0.89 | DPP4 (0.58) | SLC6A4SLC6A3SLC6A2HSD11B1DPP4 | |
| SCHEMBL6494518 | 0.86 | HSD11B1 (0.68) | SLC6A4SLC6A3SLC6A2HSD11B1CACNA1G | |
| SCHEMBL6499750 | 0.84 | HSD11B1 (0.65) | SLC6A4SLC6A3SLC6A2HSD11B1CACNA1G | |
| SCHEMBL6494941 | 0.82 | SLC6A3 (0.60) | SLC6A4SLC6A3SLC6A2HSD11B1 | |
| SCHEMBL12836593 | 0.81 | SLC6A3 (0.62) | SLC6A4SLC6A3SLC6A2HSD11B1 | |
| SCHEMBL6491320 | 0.81 | HSD11B1 (0.51) | SLC6A4SLC6A3SLC6A2HSD11B1LMNA | |
| SCHEMBL17761201 | 0.81 | HSD11B1 (0.51) | SLC6A4SLC6A3SLC6A2HSD11B1L3MBTL1 | |
| SCHEMBL17761297 | 0.81 | HSD11B1 (0.73) | SLC6A4SLC6A3SLC6A2HSD11B1CACNA1G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050234096-A1 | Tetrahydroisoquinoline derivatives | BAYER HEALTHCARE AG (DE) | 2005-10-20 | — | — | US | disclosed |
| EP-1507763-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES | Bayer HealthCare AG (DE) | 2005-02-23 | — | — | EP | disclosed |
| WO-2003097607-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234096-A1 | Tetrahydroisoquinoline derivatives | PPARD, PPARG, PPARA | SLC6A4 3525/4885SLC6A3 3645/4885SLC6A2 3869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.